Shares in Outlook Therapeutics cratered today after the FDA rejected the company's marketing application for its lead drug ONS-5010, a therapy for age-related macular dege
Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs that will be subject to Medicare pricing negotiations,
The identity of the first 10 medicines that will be subject to the first round of Medicare pricing negotiations has been revealed and, as expected, some big brands are in
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has become the first regulator to approve Roche's subcutaneous (SC) formulation of cancer immunotherapy
Bristol-Myers Squibb's blockbuster aspirations for Reblozyl have been given a boost by the FDA after it approved the drug as a first-line treatment for anaemia in patients
High-profile digital health investor Luba Greenwood recently announced that she’s joined as Chair of the Board at Closed Loop Medicine, a company applying machine learning to precision drug